Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oramed Chief Executive Officer, Nadav Kidron notes, "We expect to rapidly complete this study and hope to advance into pivotal trials for emergency use approval in countries where our oral VLP vaccine would have the greatest impact. South Africa is a great location for the Phase 1 study, as it is currently experiencing a surge in COVID cases and has struggled to obtain sufficient vaccines.
A gilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies – OCT Webinar
Agilex Biolabs has more than 140 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.
BD and CerTest Biotec Announce CE Mark for Molecular Test to Detect, Identify Certain SARS-CoV-2 Variants
VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX™ System Identifies and Differentiates Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) Variants.
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX (tecovirimat) at no cost.
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
This trial is Direct Biologics' second approved IND, and it represents the first IND ever approved by FDA for the use of extracellular vesicles (EVs) to treat Post-Acute COVID-19 syndrome, Chronic Post-COVID-19 syndrome, or any post-viral syndrome.
Lu (University of Illinois) and Techtmann (Michigan Technological University) receive prize in “Food Generation” category for research to turn plastic waste into edible food. Spinoff Prize of € 30,000 awarded to start-up HighT-Tech. Future Insight Days to conclude with the presentation of the Johann Anton Merck Award
JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
JanOne recently announced its completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101, an initial step along the path to initiation of the Phase 2b PAD trial.
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
"Fast Track Designation represents another positive step for the clinical development of LB1148 and is a clear recognition of the serious need that exists for patients looking to avoid long-lasting and serious complications from post-surgical adhesions,” said Tom Hallam, Ph.D., chief executive officer of Palisade Bio.
Today they announced additional details on the outcomes from the clinical investigation of its Bentrio nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy.
Both of these in vitro diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology.
Capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases